CAD In Women

Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors

Hypercholesterolemia has been known for several years to be a major risk factor in the development of atherosclerosis and consecutively cardiovascular disease. This epidemiological concept has been widely confirmed using different strategies that have reduced low-density lipoprotein (LDL) levels and cardiovascular events (morbidity and mortality) in primary as well as in secondary prevention, in different groups of patients.

Women with Stable Angina Pectoris and No Obstructive Coronary Artery Disease: Closer to a Diagnosis

Women have for many years been regarded as being at relatively low risk for the development of ischaemic heart disease (IHD).1,2 Recently this pattern has changed and cardiovascular disease (CVD) is now the leading cause of death for women in Europe.3,4 Under the age of 60 years acute coronary syndrome occurs 3–4 times more often in men; however, after the age of 75 years women represent the majority of the patients.

Cardiovascular Disease in Women: Understanding Symptoms and Risk Factors

Globally, cardiovascular disease (CVD) remains the leading cause of mortality in women. Approximately 2.8 million women have been diagnosed with CVD in the UK.1 For many years, the presence of gender-related differences in presentation, risk factors and outcomes have been recognised. Importantly, these discrepancies in presentation and outcomes between the sexes are often associated with inequalities in the detection, referral and management of CVD.

The Role of Myocardial Perfusion Imaging in the Clinical Evaluation of Coronary Artery Disease in Women

The American Society of Nuclear Cardiology (ASNC), founded in 1993, is a professional medical society whose mission is to foster optimal delivery of nuclear cardiology services through professional education and leadership in the establishment of standards and guidelines for the practice of nuclear cardiology. ASNC will from time to time publish Position, Policy or Consensus Statements, which reflect a body of knowledge and clinical evidence for an application of radionuclide imaging techniques in the clinical care of patients with known or suspected heart disease.